Want to see KYMR full AI Analyst Report?
Kymera Therapeutics (KYMR) Income Statement
Kymera Therapeutics Income Statement
Last quarter (Q3 2026), Kymera Therapeutics's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q3, Kymera Therapeutics's net income was $-132.00M. See Kymera Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 39.20M | $ 47.07M | $ 78.59M | $ 46.83M | $ 72.83M | |
| $ 39.20M | $ 47.07M | $ 78.59M | $ 46.83M | $ 72.83M | |
| $ 388.60M | $ 308.71M | $ 244.12M | $ 208.08M | $ 173.36M | |
| Depreciation and Amortization | $ 8.31M | $ 7.37M | $ 3.56M | $ 2.98M | $ 2.40M |
| $ -303.06M | $ -216.24M | $ -143.20M | $ -151.66M | $ -97.64M | |
| $ -349.40M | $ -261.63M | $ -165.53M | $ -161.26M | $ -100.53M | |
| $ 37.78M | $ 37.78M | $ 18.57M | $ 6.45M | $ 313.00K | |
| $ -311.62M | $ -223.86M | $ -146.96M | $ -154.81M | $ -100.22M | |
| $ -311.40M | $ -223.86M | $ -146.96M | $ -154.81M | $ -100.22M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.69 | $ -2.98 | $ -2.52 | $ -2.87 | $ -2.09 |
| Diluted EPS | $ -3.69 | $ -2.98 | $ -2.52 | $ -2.87 | $ -2.09 |
| Weighted Average Shares Outstanding | 84.39M | 75.04M | 58.37M | 53.93M | 47.99M |
| Weighted Average Shares Outstanding (Diluted) | 84.39M | 75.04M | 58.37M | 53.93M | 47.99M |
Currency in USD